FREDUN PHARMACEUTICALS
|
FREDUN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 44.07 | 33.25 | 23.84 | 14.29 | 5.05 |
| CEPS(Rs) | 53.49 | 41.32 | 30.04 | 19.16 | 10.07 |
| DPS(Rs) | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| Book NAV/Share(Rs) | 299.47 | 255.15 | 194.27 | 153.07 | 107.96 |
| Tax Rate(%) | 26.40 | 27.17 | 38.28 | 26.33 | 37.17 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.60 | 10.91 | 10.11 | 6.20 | 6.98 |
| EBIT Margin(%) | 11.16 | 10.08 | 9.75 | 5.96 | 5.66 |
| Pre Tax Margin(%) | 6.23 | 6.16 | 6.37 | 3.83 | 2.39 |
| PAT Margin (%) | 4.59 | 4.49 | 3.93 | 2.82 | 1.50 |
| Cash Profit Margin (%) | 5.57 | 5.58 | 4.96 | 3.78 | 3.00 |
| Performance Ratios | |||||
| ROA(%) | 5.24 | 5.53 | 4.86 | 3.63 | 1.33 |
| ROE(%) | 15.93 | 15.03 | 13.86 | 11.42 | 4.77 |
| ROCE(%) | 18.94 | 17.13 | 17.64 | 13.15 | 9.53 |
| Asset Turnover(x) | 1.14 | 1.23 | 1.24 | 1.29 | 0.88 |
| Sales/Fixed Asset(x) | 6.09 | 5.76 | 5.86 | 5.60 | 3.59 |
| Working Capital/Sales(x) | 4.53 | 3.85 | 3.59 | 2.84 | 3.07 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.16 | 0.17 | 0.17 | 0.18 | 0.28 |
| Receivable days | 97.31 | 52.11 | 82.94 | 106.79 | 109.11 |
| Inventory Days | 166.84 | 170.43 | 130.61 | 92.72 | 160.89 |
| Payable days | 114.86 | 85.40 | 94.41 | 111.88 | 189.53 |
| Valuation Parameters | |||||
| PER(x) | 15.17 | 21.57 | 32.60 | 64.04 | 91.79 |
| PCE(x) | 12.50 | 17.36 | 25.87 | 47.78 | 46.02 |
| Price/Book(x) | 2.23 | 2.81 | 4.00 | 5.98 | 4.29 |
| Yield(%) | 0.10 | 0.10 | 0.09 | 0.08 | 0.15 |
| EV/Net Sales(x) | 1.05 | 1.27 | 1.59 | 2.03 | 1.67 |
| EV/Core EBITDA(x) | 8.66 | 11.34 | 14.71 | 29.37 | 20.80 |
| EV/EBIT(x) | 9.42 | 12.57 | 16.25 | 34.10 | 29.49 |
| EV/CE(x) | 1.55 | 1.94 | 2.38 | 2.44 | 1.38 |
| M Cap / Sales | 0.70 | 0.97 | 1.28 | 1.81 | 1.38 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 30.35 | 26.75 | 22.37 | 67.64 | 18.73 |
| Core EBITDA Growth(%) | 41.64 | 31.41 | 90.46 | 44.65 | 21.42 |
| EBIT Growth(%) | 44.29 | 31.03 | 100.16 | 76.67 | 8.70 |
| PAT Growth(%) | 33.18 | 44.57 | 70.58 | 214.45 | 5.93 |
| EPS Growth(%) | 32.55 | 39.44 | 66.83 | 183.03 | 5.93 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.18 | 0.88 | 0.98 | 0.78 | 0.92 |
| Current Ratio(x) | 1.31 | 1.54 | 1.55 | 2.07 | 1.50 |
| Quick Ratio(x) | 0.57 | 0.49 | 0.47 | 1.44 | 0.72 |
| Interest Cover(x) | 2.26 | 2.57 | 2.89 | 2.80 | 1.73 |
| Total Debt/Mcap(x) | 0.53 | 0.31 | 0.25 | 0.13 | 0.21 |
Compare Financial Ratios of peers of FREDUN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| FREDUN PHARMACEUTICALS | ₹836.9 Cr | -8.1% | 14.8% | 140.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹430,753.0 Cr | -0.2% | 6.1% | 0.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,998.0 Cr | -1.4% | -4.9% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,186.0 Cr | 0.8% | 5% | 12.9% | Stock Analytics | |
| CIPLA | ₹120,960.0 Cr | -1.3% | -0.5% | 1.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,759.0 Cr | -0.7% | 5.1% | 4.9% | Stock Analytics | |
FREDUN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| FREDUN PHARMACEUTICALS | -8.1% |
14.8% |
140.2% |
| SENSEX | -0.6% |
2.2% |
5.3% |
You may also like the below Video Courses
